Drugs / Deuteporfin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02955771 | May 2017 → Dec 2018 | hilar cholangiocarcinoma | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01481597 Comparator | Nov 2011 → Apr 2012 | — | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | deuteporfin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01481597 ↗ |
| Route | Intravenous | “deuteporfin 1 mg/kg IV as a single dose” NCT01481597 ↗ |